PHIBRO ANIMAL HEALTH CORP (PAHC) FY2025 10-K Annual Report
PHIBRO ANIMAL HEALTH CORP (PAHC) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Aug 27, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
PHIBRO ANIMAL HEALTH CORP FY2025 10-K Analysis
Business Overview
- • Core business model: Global animal health and mineral nutrition solutions for livestock and companion animals, marketing ~800 product lines across 90 countries
- • New acquisition: Zoetis medicated feed additive portfolio acquired for $297.5M, adding $208.2M net sales in FY25 and 6 manufacturing sites in US, Italy, China
- • Strategic shift: Significant expansion in Animal Health segment driven by MFA product portfolio acquisition, Animal Health sales grow 36% to $963M
- • Notable metric: Total net sales up 27% YoY to $1.296B; Animal Health segment EBITDA up 53% to $222M; net assets increase 39% to $1.361B
- • Unusual fact: Inclusion of armed conflicts’ impact on results in MD&A due to ongoing geopolitical risks in Middle East and Eastern Europe
Management Discussion & Analysis
- • Revenue $1.296B, up 27% YoY from $1.018B; Animal Health best segment $963M, up 36% YoY; Performance Products worst $80.2M, up 19%
- • Adjusted net income $84.9M, up 76% YoY from $48.4M; adjusted diluted EPS $2.09 vs $1.19 prior year
- • Operating margin ~8.5% ($110.5M operating income on $1,296M sales) up vs $53.3M on $1,018M (~5.2%) prior year calculated from given data
- • Operating cash flow $80.1M vs $87.6M prior year; Capital expenditures $38.3M vs $41.2M; Financing activities net cash inflow $207.1M (refinancing and acquisition financing); dividends paid $19.4M
- • Management expects adequate liquidity for next 12 months; risks include macroeconomic uncertainty, geopolitical conflicts (Israel-Hamas, Russia-Ukraine), and debt covenant restrictions on investments and dividends
Risk Factors
- • Cybersecurity attacks increasing in sophistication, with potential for material business impact
- • AI technology adoption risks, including compliance with privacy regulations and ethical use across enterprise
- • Dependency on third-party suppliers with ongoing cybersecurity regulatory risk monitoring and standardized risk evaluations
- • Key-person risk: CIO with 45 years' experience critical to information security and risk management programs
- • Cyber insurance coverage regularly reviewed to support layered protection against cybersecurity incidents
PHIBRO ANIMAL HEALTH CORP FY2025 Key Financial MetricsXBRL
Revenue
$1.3B
▲ +27.4% YoY
Net Income
$48M
▲ +1897.7% YoY
Gross Margin
30.9%
▲ +9bp YoY
Operating Margin
8.5%
▲ +328bp YoY
Net Margin
3.7%
▲ +349bp YoY
ROE
16.9%
▲ +1595bp YoY
Total Assets
$1.4B
▲ +38.6% YoY
EPS (Diluted)
$1.19
▲ +1883.3% YoY
Operating Cash Flow
$80M
▼ -8.5% YoY
Source: XBRL data from PHIBRO ANIMAL HEALTH CORP FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on PHIBRO ANIMAL HEALTH CORP
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.